Table 4.
Novel or tested molecular mechanistic hypotheses
| Drug 1 | Drug 2 | DDI dosing recommendations in drug labels (D1/D2) | Drug-drug interaction effects | Shared genes | Novel molecular mechanistic hypotheses | PMIDs for tested hypotheses |
|---|---|---|---|---|---|---|
| Ramipril | Hydrochlorothiazide | n/a | Improved blood pressure reduction | ACE rs4359 or rs4344 | Yes | - |
| Azathioprine | Mercaptopurine | n/a | An increased risk of pancreatitis |
HLA-DQA1 (*02:01 allele), HLA-DRB1 (*07:01 allele) |
Yes | - |
| Etanercept | Methotrexate | 50 mg etanercept once weekly | Increased efficacy in patients with rheumatoid arthritis |
ATP5F1E rs1059150, HLA-E rs1264457, KLRC1 rs7301582 |
Yes | - |
| Amlodipine | Benazepril | 2.5 mg/10 mg o.d, 10 mg/40 mg o.d maintenance | Improved blood pressure reduction | ACE rs1799752 | Yes | - |
| Raltitrexed | Irinotecan | n/a | Increased incidence of asthenia |
TYMS
rs45445694 |
No | 9607593 |
| Cisplatin | Pemetrexed | 500 mg/m2 i.v and 75 mg/m2 i.v | Improved response rate in mesothelioma |
ABCC2
rs2273697, MTHFR rs1801133, SLC19A1 rs1051298 |
No | 16898269, 22562354 |
| Carbamazepine | Levetiracetam | n/a | Leads to beneficial anticonvulsant pharmacodynamic interactions |
SCN1A
rs2298771 |
No | 24211788 |
DDI: drug-drug interactions, PMID: PubMed ids for journal articles, n/a: not available, o.d: once a day, i.v: intra-venous administration